Form 4 for DGX Quest Diagnostics
Accepted 2025-10-24 00:00:00 ET · period of report 2025-10-21 · accession 0001022079-25-000225 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-24 | 2025-10-21 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | A - Grant | $189.08 | +15 | 7,530 | +0.2% | +$2,836 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-21 | A | A | 15 | $189.08 | 7,530 | D | — | — | (F1) Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. |